REGN

Regeneron Pharmaceuticals Inc

May 18 • 12:10PM ET

628.10

-70.15 -10.05 %

Healthcare • Biotechnology • USA • Large • NASD

Today, 10:15 AMRegeneron fianlimab plus cemiplimab Phase 3 melanoma trial misses primary endpoint vs pembrolizumab, triggering Leerink and Citi downgrades

Peers: AMGN VRTX GILD INCY ALNY EXEL BMRN MRNA BIIB HALO

| Held by: VTI VOO QQQ IVV SPY VTV JEPI IBB XLV QQQM

Scroll to Statements

Index	NDX, S&P 500	P/E	15.30	EPS (ttm)	41.04	Insider Own	3.74%	Shs Outstand	103.20M	Perf Week	-11.88%
Market Cap	65.85B	Forward P/E	11.60	EPS next Y	54.15	Insider Trans	-0.16%	Shs Float	100.91M	Perf Month	-16.32%
Enterprise Value	59.79B	PEG	1.04	EPS next Q	10.85	Inst Own	86.76%	Short Float	3.24%	Perf Quarter	-20.85%
Income	4.42B	P/S	4.41	EPS this Y	4.74%	Inst Trans	-0.77%	Short Ratio	4.77	Perf Half Y	-9.62%
Sales	14.92B	P/B	2.10	EPS next Y	16.68%	ROA	11.28%	Short Interest	3.27M	Perf YTD	-18.63%
Book/sh	299.27	P/C	7.52	EPS next 5Y	11.17%	ROE	14.55%	52W High	821.11 -23.51%	Perf Year	5.68%
Cash/sh	83.57	P/FCF	16.01	EPS past 3/5Y	2.76% 6.33%	ROIC	13.24%	52W Low	476.49 31.82%	Perf 3Y	-15.97%
Dividend Est.	3.97 (0.63%)	EV/EBITDA	13.64	Sales past 3/5Y	5.62% 11.04%	Gross Margin	80.93%	Volatility	2.80% 2.60%	Perf 5Y	21.67%
Dividend TTM	3.58 (0.57%)	EV/Sales	4.01	EPS Y/Y TTM	1.85%	Oper. Margin	25.76%	ATR (14)	24.60	Perf 10Y	60.94%
Dividend Ex-Date	May 20, 2026	Quick Ratio	2.96	Sales Y/Y TTM	5.92%	Profit Margin	29.65%	RSI (14)	25.75	Recom	1.71
Dividend Gr. 3/5Y	- -	Current Ratio	3.57	EPS Q/Q	-7.16%	SMA20	-12.36%	Beta	0.29	Target Price	846.77
Payout	8.49%	Debt/Eq	0.09	Sales Q/Q	19.04%	SMA50	-15.09%	Rel Volume	6.01	Prev Close	698.25
Employees	15410	LT Debt/Eq	0.06	Earnings	Apr 29 BMO	SMA200	-9.21%	Avg Volume	686.05K	Price	628.10
IPO	Apr 02, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.24% 3.59%	Trades		Volume	1,813,214	Change	-10.05%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	Leerink Partners	Outperform → Market Perform	$641
Today	Downgrade	Citigroup	Buy → Neutral	$700
Mar-31-26	Resumed	Piper Sandler	Overweight	$875
Mar-06-26	Initiated	Barclays	Overweight	$923
Jan-07-26	Upgrade	BofA Securities	Underperform → Buy	$860
Dec-03-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$767
Nov-24-25	Resumed	Truist	Buy	$798
Nov-24-25	Initiated	HSBC Securities	Buy	$255
Nov-13-25	Initiated	Scotiabank	Sector Perform	$650
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy	$890
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$580
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$662
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895

Show Previous Ratings

Today 10:17AM	Regeneron Stock Tumbles on Melanoma Drug Trial Miss (The Wall Street Journal) -10.05%
10:05AM	Regeneron drops after skin cancer treatment fails late-stage trial (Reuters)
09:55AM	Zscaler upgraded, CoreWeave downgraded: Wall Street's top analyst calls (The Fly)
09:26AM	The Surprising Reason Regeneron Pharmaceuticals Just Dropped 12% (Investor's Business Daily)
08:28AM	Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda (Proactive)
08:22AM	Loading…
08:22AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:57AM	LiveRamp's stock soars after France's Publicis Groupe said it would acquire the company in $2.2 billion deal (MarketWatch)
07:28AM	Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda (Barrons.com)
07:04AM	Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints (The Wall Street Journal)
07:00AM	Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas (GlobeNewswire)
06:19AM	Regeneron slides after melanoma study misses key endpoint (REGN) (InvestorsHub)
05:11AM	Regeneron shares fall 12% on disappointing melanoma trial data (Investing.com)
May-17-26 12:52PM	Health officials declare Ebola outbreak a public health emergency (MarketWatch)
May-15-26 08:19PM	Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma (GlobeNewswire) -10.05%
02:09PM	Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair (GlobeNewswire)
08:27AM	Loading…
May-09-26 08:27AM	The Nasdaq's top winners are now running hotter than in 2000: Chart of the Day (Yahoo Finance)
May-08-26 07:00AM	Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years (GlobeNewswire)
May-07-26 06:45AM	Trumps Affordability Push Stalls Ahead of Midterm Elections (Bloomberg)
May-05-26 10:14AM	Regeneron (REGN) Dupixent Phase 4 Trial Results Show Improved Esophageal Function in EoE (InvestorsHub)
07:00AM	Dupixent (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial (GlobeNewswire)
May-01-26 06:51AM	Bristol Myers legacy lift, Biogens blue skies and Regenerons murky outlook (BioPharma Dive)
Apr-30-26 04:06PM	Amgen's Numbers Are Out: It Gets To Keep Its Cholesterol Crown - For Now (Investor's Business Daily)
05:24AM	Regeneron Q1 2026 net income falls 10% to $727m (Pharmaceutical Technology)
Apr-29-26 12:47PM	Regeneron Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby) -6.21%
10:12AM	Regeneron shares slide despite Q1 beat (Proactive)
09:10AM	Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug (Investor's Business Daily)
08:53AM	Regeneron Tops Q1 Estimates on Dupixent Momentum (InvestorsHub)
08:23AM	General Dynamics, ADP rise premarket; SoFi Technologies slides (Investing.com)
08:02AM	Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. (Barrons.com)
07:15AM	Regeneron beats first quarter estimates on Dupixent strength (Investing.com)
06:40AM	Loading…
06:40AM	Regeneron: Q1 Earnings Snapshot (Associated Press)
06:30AM	Regeneron Reports First Quarter 2026 Financial and Operating Results (GlobeNewswire)
05:03AM	Big-tech earnings bonanza after closing bell (MarketWatch)
04:22AM	Stock Market Today: Dow, S&P 500 and Nasdaq set to rise ahead of host of tech earnings; Fed interest-rate decision due (MarketWatch)
Apr-27-26 02:47AM	Coultreon banks $125M to support testing of former Galapagos immune drug (BioPharma Dive)
Apr-24-26 11:00AM	Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims (Yahoo Finance Video)
07:12AM	Regeneron cuts White House pricing deal, offers new gene therapy for free (Pharmaceutical Technology)
06:46AM	Lilly tumbles on Foundayos shaky week; FDA to issue vouchers for psychedelics (BioPharma Dive)
Apr-23-26 06:54PM	'Two ways of calculating': Trump defends his mathematically impossible calculations on drug prices (Associated Press)
05:49PM	Regeneron Shares Up on Trump Drug Pricing Deal (Barrons.com)
03:46PM	Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S. (GlobeNewswire)
12:40PM	Otarmeni (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. (GlobeNewswire)
03:48AM	Sanofi climbs as strong Dupixent sales drive Q1 revenue and profit beat (Investing.com)
Apr-22-26 05:30PM	Dupixent (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
Apr-21-26 10:30AM	Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial (GlobeNewswire)
Apr-20-26 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
Apr-15-26 04:04PM	Trump's new tax cuts are helping millions: Treasury Sec. Bessent (Yahoo Finance Video)
Apr-14-26 04:55AM	Novo teams with OpenAI; Ideaya gets muted response to eye drug data (BioPharma Dive)
Apr-13-26 06:59AM	Telix and Regeneron to co-develop radiopharmaceutical therapies (Pharmaceutical Business Review)
06:48AM	Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies (Pharmaceutical Technology)
06:30AM	Regeneron and Telix Announce Strategic Radiopharma Collaboration (GlobeNewswire)
01:00AM	Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
Apr-02-26 04:30PM	TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions (PR Newswire)
04:30PM	Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions (GlobeNewswire)
03:41PM	Trump Administration Unveils Up to 100% Tariff on Branded Drugs (The Wall Street Journal)
03:39PM	Trump Slaps 100% Tariffs on Some Drug Imports. What to Know. (Barrons.com)
12:00PM	EYLEA HD (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) (GlobeNewswire)
Mar-27-26 07:56AM	AstraZeneca lung drug gets surprise win in COPD trials (BioPharma Dive)
Mar-25-26 04:05PM	Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026 (GlobeNewswire)
Mar-24-26 02:00AM	Dupixent (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP) (GlobeNewswire)
Mar-23-26 10:01AM	How Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema Drug (Investor's Business Daily)
08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
Mar-19-26 01:51PM	Wall Street Faces a $5.7 Trillion Triple-Witching Jolt on Friday (Bloomberg)
Mar-10-26 09:29PM	Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment (GlobeNewswire)
07:00AM	Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy (BioPharma Dive)
Mar-09-26 10:38PM	Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss (24/7 Wall St.)
08:31PM	Analyst Report: Sanofi (Morningstar Research)
07:00AM	Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients (GlobeNewswire)
Mar-06-26 07:54AM	Here Are Fridays Top Wall Street Analyst Research Calls: BorgWarner, CoreWeave, Intuit, Marvell Technology, Netflix, Okta, Regeneron Pharmaceuticals, Trade Desk, and More (24/7 Wall St.)
Mar-05-26 04:05PM	Regeneron Announces Investor Conference Presentation (GlobeNewswire)
11:30AM	Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report? (Zacks)
Mar-04-26 05:51PM	COWG Is Up While QQQ Slips. What the Free Cash Flow Screen Is Actually Doing (24/7 Wall St.)
11:02AM	Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales (Zacks)
10:09AM	Jim Cramer Says "I Should Have Pulled the Trigger on Regeneron" (Insider Monkey)
Mar-03-26 07:49PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
10:50AM	Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU (Zacks)
09:20AM	Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study (Zacks)
Mar-02-26 06:44PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
09:10AM	REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria (Zacks)
Feb-28-26 02:21AM	Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds (Insider Monkey)
12:19AM	Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq? (Barchart)
Feb-27-26 11:14AM	Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline (Zacks)
08:30AM	OPKO Health, Inc. Q4 2025 Earnings Call Summary (Moby)
07:00AM	Dupixent (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment (GlobeNewswire)
01:12AM	OPKO Health Q4 Earnings Call Highlights (MarketBeat)
12:06AM	OPKO Health Inc (OPK) Q4 2025 Earnings Call Highlights: Strategic Divestitures and Promising ... (GuruFocus.com)
Feb-26-26 12:00PM	Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders (GlobeNewswire)
Feb-24-26 01:47PM	Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition (Benzinga)
09:30AM	Dupixent (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS) (GlobeNewswire)
02:11AM	FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review (Insider Monkey)
Feb-23-26 02:20PM	Why IBD Stock Of The Day Harrow Has Its Sights On A Breakout (Investor's Business Daily)
10:35AM	Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings? (Zacks)
Feb-20-26 08:11AM	Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock? (Barchart)
Feb-19-26 06:01PM	Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes (Benzinga)
09:53AM	Here's What Analysts Are Saying About Regeneron Pharmaceuticals (REGN) (Insider Monkey)
08:21AM	AtaiBeckley names Michael Faerm as finance chief (Proactive)
07:00AM	Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) (GlobeNewswire)
Feb-17-26 09:15AM	Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes (Benzinga)
08:30AM	Ocular Therapeutix stock news: Why positive data led to a 25% drop (Investing.com)
Feb-13-26 01:45PM	CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens (Benzinga)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Ph.D.Dr. Leonard S. Schleifer M.D.

Ph.D.Dr. George D. Yancopoulos M.D.

Executive VP of Finance & CFOMr. Christopher R. Fenimore CPA

Executive VPMr. Joseph J. LaRosa J.D.

Executive VP of Research & Co-Chief Scientific OfficerDr. Andrew J. Murphy Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RYAN ARTHUR F	Director	May 01 '26	Sale	705.24	100	70,524	17,503	May 04 04:14 PM
RYAN ARTHUR F	Director	Apr 01 '26	Sale	777.27	100	77,727	17,603	Apr 03 04:01 PM
RYAN ARTHUR F	Director	Mar 02 '26	Sale	785.50	100	78,550	17,703	Mar 03 04:01 PM
Zoghbi Huda Y	Director	Feb 19 '26	Option Exercise	376.69	1,638	617,018	3,341	Feb 23 04:55 PM
Zoghbi Huda Y	Director	Feb 19 '26	Sale	781.33	1,638	1,279,812	1,703	Feb 23 04:55 PM
Zoghbi Huda Y	Director	Feb 19 '26	Proposed Sale	790.00	1,638	1,294,020		Feb 19 04:04 PM
Pitofsky Jason	SVP Controller	Feb 09 '26	Option Exercise	492.00	1,000	492,000	6,308	Feb 11 04:03 PM
Pitofsky Jason	SVP Controller	Feb 09 '26	Sale	778.52	2,036	1,585,058	4,272	Feb 11 04:03 PM
RYAN ARTHUR F	Director	Feb 09 '26	Sale	778.53	100	77,853	17,803	Feb 11 04:02 PM
Arthur F. Ryan	Director	Feb 09 '26	Proposed Sale	785.51	400	314,204		Feb 09 05:02 PM
Pitofsky Jason	Officer	Feb 09 '26	Proposed Sale	783.17	2,036	1,594,534		Feb 09 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Option Exercise	374.12	1,500	561,180	3,203	Jan 08 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Sale	800.00	1,500	1,200,000	1,703	Jan 08 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Proposed Sale	800.00	1,500	1,200,000		Jan 07 12:03 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Dec 31 '25	Option Exercise	0.00	28,570	0	339,030	Jan 05 05:54 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Dec 31 '25	Option Exercise	0.00	28,570	0	243,093	Jan 05 05:53 PM
SING GEORGE L	Director	Dec 30 '25	Option Exercise	520.01	9,212	4,790,332	37,040	Dec 31 05:05 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Dec 09 '25	Option Exercise	555.67	146,815	81,580,691	442,334	Dec 11 04:27 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Dec 09 '25	Option Exercise	555.67	172,723	95,976,989	369,668	Dec 11 04:23 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Nov 20 '25	Option Exercise	555.67	14,450	8,029,431	35,525	Nov 24 04:07 PM
Bassler Bonnie L	Director	Nov 20 '25	Option Exercise	371.40	760	282,264	2,308	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Sale	750.00	760	570,000	1,548	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Proposed Sale	750.00	760	570,000		Nov 20 02:31 PM
Pitofsky Jason	VP Controller	Nov 07 '25	Sale	651.43	431	280,766	4,233	Nov 10 04:37 PM
Jason Pitofsky	Officer	Nov 07 '25	Proposed Sale	651.00	431	280,581		Nov 07 05:06 PM
POON CHRISTINE A	Director	Oct 29 '25	Option Exercise	520.01	6,500	3,380,065	8,852	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 30 '25	Option Exercise	520.01	2,712	1,410,267	5,064	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 29 '25	Sale	654.27	6,500	4,252,745	2,352	Oct 31 04:09 PM
MURPHY ANDREW J	EVP Research	Oct 29 '25	Option Exercise	555.67	35,000	19,448,450	84,074	Oct 31 04:06 PM
Christine Poon	Director	Oct 29 '25	Proposed Sale	652.91	6,500	4,243,915		Oct 29 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals Inc

Upgrade your Finviz experience